As with oncology, the broad church of'inflammation and immune modulation'has proven attractive for Pharma companies, who have been enticed by the
摘要：
Wenzel S, et al. Dupilumab in persistent asthma with elevated eosinophil levels. PavordID et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre,double-blind, placebo-controlled trial. Lancet 2012; 380: 651– 659.
展开
通过文献互助平台发起求助，成功后即可免费获取论文全文。
请先登入
相似文献
参考文献
引证文献
辅助模式
0
引用
文献可以批量引用啦~
欢迎点我试用！
